VIMTALABS

Vimta Labs Share Price

₹1,041.25 +38.2 (3.81%)

12 Mar, 2025 07:12

SIP TrendupStart SIP in VIMTALABS

Start SIP

Performance

  • Low
  • ₹948
  • High
  • ₹1,048
  • 52 Week Low
  • ₹420
  • 52 Week High
  • ₹1,178
  • Open Price₹980
  • Previous Close₹1,003
  • Volume254,949

Investment Returns

  • Over 1 Month -0.41%
  • Over 3 Month + 13.33%
  • Over 6 Month + 61.72%
  • Over 1 Year + 123.83%
SIP Lightning

Smart Investing Starts Here Start SIP with Vimta Labs for Steady Growth!

Invest Now

Vimta Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.7
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 2,314
  • P/B Ratio
  • 6.8
  • Average True Range
  • 72.88
  • EPS
  • 27.35
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -2.34
  • RSI
  • 60.26
  • MFI
  • 61.97

Vimta Labs Financials

Vimta Labs Technicals

EMA & SMA

Current Price
₹1,041.25
+ 38.2 (3.81%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹944.80
  • 50 Day
  • ₹924.78
  • 100 Day
  • ₹859.72
  • 200 Day
  • ₹752.04

Resistance and Support

1012.4 Pivot Speed
  • R3 1,176.75
  • R2 1,112.35
  • R1 1,076.80
  • S1 976.85
  • S2 912.45
  • S3 876.90

What's your outlook on Vimta Labs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vimta Labs Ltd. offers a wide range of testing, inspection, and analytical services, specializing in pharmaceuticals, food, and environmental testing. Serving clients globally, it provides high-quality, accredited lab services to ensure product safety and regulatory compliance.

Vimta Labs has an operating revenue of Rs. 336.11 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 17% is great, ROE of 12% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 44% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -6% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 96 which is a GREAT score indicating consistency in earnings, a RS Rating of 94 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Services and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vimta Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-24 Quarterly Results
2024-11-08 Quarterly Results
2024-07-17 Quarterly Results
2024-05-18 Audited Results & Final Dividend
2024-03-30 Amalgamation
Date Purpose Remarks
2022-06-18 FINAL Rs.2.00 per share(100%)Dividend
2021-06-28 FINAL Rs.2.00 per share(100%)Dividend
View More

Vimta Labs F&O

Vimta Labs Shareholding Pattern

36.76%
0.13%
3.81%
0.02%
25.09%
34.19%

About Vimta Labs

  • NSE Symbol
  • VIMTALABS
  • BSE Symbol
  • 524394
  • Managing Director
  • Ms. Harita Vasireddi
  • ISIN
  • INE579C01029

Similar Stocks to Vimta Labs

Vimta Labs FAQs

Vimta Labs share price is ₹1,041 As on 12 March, 2025 | 06:58

The Market Cap of Vimta Labs is ₹2313.9 Cr As on 12 March, 2025 | 06:58

The P/E ratio of Vimta Labs is 37.7 As on 12 March, 2025 | 06:58

The PB ratio of Vimta Labs is 6.8 As on 12 March, 2025 | 06:58

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23